January 23, 2019
Biohaven in new phase testing glutamate modulator for AD patients
Biohaven Pharmaceutical started a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer’s disease (AD).